Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1872-3128
  • E-ISSN: 1874-0758

Abstract

Background: CYP450 enzymes in the liver have a significant role in the metabolism of xenobiotics. Probe drug strategy is broadly used to evaluate the pharmacodynamic and pharmacokinetic drug/ herb-drug interactions/ food-drug interactions. Probe drugs reveal the exact pathway of drug metabolism in the liver by their targeted tractability property. The CYP3A4 isoenzyme metabolizes the majority of the drugs (65%). Methods: The characteristics of targeted probe drugs were observed from the admetSAR (version2) online database. Results: Midazolam is widely used as a probe drug because of its peculiar character. Midazolam affirms the accurate and consistent prediction of pharmacokinetic mediated drug interactions even in nanogram concentrations with or without a potent CYP3A inhibitor. Remarkably, midazolam is used as a CYP3A4 substrate in the majority of in vivo studies. Conclusion: It is concluded that midazolam shows a good response in all clinical studies because of its lesser half-life and bioavailability when compared with other probe drugs.

Loading

Article metrics loading...

/content/journals/dml/10.2174/1872312814666200811110024
2021-03-01
2025-06-21
Loading full text...

Full text loading...

/content/journals/dml/10.2174/1872312814666200811110024
Loading

  • Article Type:
    Other
Keyword(s): CAM; CYP3A4; drug interactions; inhibitor; midazolam; Probe drug; substrates
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test